Overview
The EasySep™ Release Human PE Positive Selection Kit is designed to isolate cells that are labeled with PE-conjugated antibodies from fresh or previously frozen peripheral blood mononuclear cells or washed leukapheresis samples by immunomagnetic positive selection.
Desired cells are labeled with antibodies and magnetic particles, and separated without columns using an EasySep™ magnet. Unwanted cells are simply poured off, while desired cells remain in the tube. Then, bound magnetic particles are removed from the EasySep™-isolated, PE-antibody labeled cells, which are immediately available for downstream applications. Following cell isolation with this EasySep™ Release kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins or other chemically related ligands.
This product replaces the EasySep™ Human PE Positive Selection Kit (Catalog #18551), providing highly purified particle-free cells.
Desired cells are labeled with antibodies and magnetic particles, and separated without columns using an EasySep™ magnet. Unwanted cells are simply poured off, while desired cells remain in the tube. Then, bound magnetic particles are removed from the EasySep™-isolated, PE-antibody labeled cells, which are immediately available for downstream applications. Following cell isolation with this EasySep™ Release kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins or other chemically related ligands.
This product replaces the EasySep™ Human PE Positive Selection Kit (Catalog #18551), providing highly purified particle-free cells.
Advantages:
• Highly purified cells labeled with PE-conjugated antibodies isolated from human or mouse tissues in less than 40 minutes
• No-wash removal of EasySep™ Releasable RapidSpheres™
• No-wash removal of EasySep™ Releasable RapidSpheres™
Components:
- EasySep™ Release Human PE Positive Selection Kit (Catalog #17654)
- EasySep™ Release PE Positive Selection Cocktail, 0.5 mL
- EasySep™ Releasable RapidSpheres™ 50201, 1 mL
- EasySep™ Release Buffer (Concentrate), 3 x 1 mL
- Anti-Human CD32 Blocker, 1 mL
Magnet Compatibility:
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyPlate™ Magnet (Catalog #18102)
• EasyEights™ Magnet (Catalog #18103)
Subtype:
Cell Isolation Kits
Cell Type:
B Cells; Dendritic Cells; Granulocytes and Subsets; Hematopoietic Stem and Progenitor Cells; Macrophages; Marrow Stromal Cells; Mesenchymal Stem and Progenitor Cells; Monocytes; Mononuclear Cells; Myeloid Cells; NK Cells; Other; Plasma; T Cells
Species:
Human
Sample Source:
Leukapheresis; Other; PBMC
Selection Method:
Positive
Application:
Cell Isolation
Brand:
EasySep
Area of Interest:
Immunology
Scientific Resources
Product Documentation
Document Type
Product Name
Catalog #
Lot #
Language
17654
19E102695 or lower
17654
1000005896 and higher
Educational Materials
(8)Data and Publications
Data

Starting with fresh PBMCs, the purities of the start and final isolated fractions are 46.9% and 98.8%, respectively, using a PE-conjugated anti-human CD45RO antibody and EasySep™ Release Human Positive Selection Kit.
Publications
(1)
Frontiers in immunology 2020
Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Na\ive T Cells."
Abstract
Abstract
Background: Differences in DNA methylation have been reported in B and T lymphocyte populations, including CD4+ T cells, isolated from rheumatoid arthritis (RA) patients when compared to healthy controls. CD4+ T cells are a heterogeneous cell type with subpopulations displaying distinct DNA methylation patterns. In this study, we investigated DNA methylation using reduced representation bisulfite sequencing in two CD4+ T cell populations (CD4+ memory and na{\{i}}ve cells) in three groups: newly diagnosed disease modifying antirheumatic drugs (DMARD) na{\"{i}}ve RA patients (N = 11) methotrexate (MTX) treated RA patients (N = 18) and healthy controls (N = 9) matched for age gender and smoking status. Results: Analyses of these data revealed significantly more differentially methylated positions (DMPs) in CD4+ memory than in CD4+ na{\""{i}}ve T cells (904 vs. 19 DMPs) in RA patients compared to controls. The majority of DMPs (72{\%}) identified in newly diagnosed and DMARD na{\""{i}}ve RA patients with active disease showed increased DNA methylation (39 DMPs) whereas most DMPs (80{\%}) identified in the MTX treated RA patients in remission displayed decreased DNA methylation (694 DMPs). Interestingly we also found that about one third of the 101 known RA risk loci overlapped (±500 kb) with the DMPs. Notably introns of the UBASH3A gene harbor both the lead RA risk SNP and two DMPs in CD4+ memory T cells. Conclusion: Our results suggest that RA associated DNA methylation differences vary between the two T cell subsets but are also influenced by RA characteristics such as disease activity disease duration and/or MTX treatment."""
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.